382 related articles for article (PubMed ID: 28094456)
1. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
2. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
[TBL] [Abstract][Full Text] [Related]
3. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
[TBL] [Abstract][Full Text] [Related]
4. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
[TBL] [Abstract][Full Text] [Related]
5. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
[TBL] [Abstract][Full Text] [Related]
6. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2021 Feb; 96(2):258-269. PubMed ID: 33368476
[TBL] [Abstract][Full Text] [Related]
7. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
[TBL] [Abstract][Full Text] [Related]
8. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2011 May; 86(5):411-6. PubMed ID: 21523800
[TBL] [Abstract][Full Text] [Related]
9. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
11. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
12. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
[TBL] [Abstract][Full Text] [Related]
13. Waldenstrom macroglobulinemia: prognosis and management.
Oza A; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
15. Waldenström macroglobulinemia.
Kasi PM; Ansell SM; Gertz MA
Clin Adv Hematol Oncol; 2015 Jan; 13(1):56-66. PubMed ID: 25679974
[TBL] [Abstract][Full Text] [Related]
16. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
17. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
[TBL] [Abstract][Full Text] [Related]
18. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
20. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
